Cancer Genetics Stock Price

-0.07 (-1.76%)
Upgrade to Real-Time
Regular Market
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Cancer Genetics Inc CGIX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.07 -1.76% 3.91 14:39:40
Open Price Low Price High Price Close Price Prev Close
3.95 3.90 4.09 3.98
Bid Price Ask Price Spread News
3.91 3.93 0.02 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
966 149,532 $ 3.97 $ 593,560 868,525 1.92 - 10.39
Last Trade Time Type Quantity Stock Price Currency
14:39:40 500 $ 3.91 USD

Cancer Genetics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 15.97M 4.09M 3.99M $ 12.32M $ -11.75M -3.84 -2.20
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Cancer Genetics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CGIX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.265.953.215.382,366,3070.6519.94%
1 Month2.755.952.614.421,088,1971.1642.18%
3 Months2.205.952.163.63726,2141.7177.73%
6 Months3.1410.392.10765.541,244,6920.7724.52%
1 Year4.1810.391.925.45655,080-0.27-6.46%
3 Years61.5066.001.928.061,157,343-57.59-93.64%
5 Years77.10159.001.9215.56770,153-73.19-94.93%

Cancer Genetics Description

Cancer Genetics Inc is in the early stage of precision medicine, enabling individualized therapies in the field of oncology through diagnostic products and services and molecular markers. The company develops, commercializes and provides molecular- and biomarker-based tests and services that enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment. It also enables biotech and pharmaceutical companies to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. The company derives most of its revenue from the United States.

Your Recent History
Cancer Gen..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.